Abstract:The management of neuroendocrine neoplasia remains a perplexing problem because of the lack of knowledge of the biology of the disease, its late presentation, the relative insensitivity of imaging modalities and a paucity of predictably effective treatment options. A critical limitation is posed by the lack of accurate biomarkers to guide management, monitor the efficacy of therapy and provide a prognostic assessment of disease progress. Currently utilized monoanalyte biomarkers (e.g. chromogranin, serotonin, pancreastatin etc.) exhibit variable metrics, poor sensitivity, specificity, and predictive ability and are rarely used to guide clinical decision making. A National Cancer Institute Neuroendocrine Tumor summit conference held in 2007 noted biomarker limitations to be a crucial unmet need in the management of neuroendocrine tumors. Nevertheless little progress has been made in this field until recently with the consideration of blood transcript analysis, circulating tumor cells and miRNA measurement. Given the complexity and multidimensionality of the neoplastic process itself, the heterogeneity of neuroendocrine tumors (NET) as well as the interaction of the tumor microenvironment, it is not unexpected that no single (monoanalyte) biomarker has proven to be effective. This deduction reflects the growing recognition that use of a monoanalyte to define a multidimensional disease process has inherent flaws. Logic dictates that no single measured parameter can capture the pathobiological diversity of neoplasia and monoanalytes cannot define the multiple variables (proliferation, metabolic activity, invasive potential and metastatic propensity) that constitute tumor growth. Thus far, most biomarkers whether in tissue or blood/urine have been single analytes with varying degrees of sensitivity and specificity and in general have failed to exhibit robust metrics or lacked methodological rigor. Neuroendocrine (NE) disease represents an area of biomarker paucity since the individual biomarkers (gastrin, insulin etc) are not widely applicable to the diverse types of NE neoplasia (NEN). Broad spectrum markers such as CgA have limitations in sensitivity, specificity and reproducibility. This review serves to provide a general background of the evolution of NET biomarkers. It provides an assessment of their current and past usage and limitations in assessing their diagnostic, pathologic and prognostic aspects in respect of NET. It provides a view of the changing methodology of biomarker development and the application of biomathematical analyses to redefining detection and treatment. Finally, it presents a description and consensus on current advances in transcript analysis, miRNA measurement and circulating tumor cell identification.

[Advances in Basic and Translational Research in Neuroendocrine Neoplasms].

Research frontiers and reflections on neuroblastoma

Advances in the Diagnosis and Management of Well-Differentiated Neuroendocrine Neoplasms

The Landscape and Clinical Application of the Tumor Microenvironment in Gastroenteropancreatic Neuroendocrine Neoplasms

Recent Research Hotspots in Sequencing and the Pancreatic Neuroendocrine Tumor Microenvironment.

Translational progress on tumor biomarkers.

Clinicopathologic feature and treatment progress of high-grade ovarian neuroendocrine tumors

The Mutational, Prognostic, and Therapeutic Landscape of Neuroendocrine Neoplasms

Advances in Translational Medicine of Basic Breast Cancer

Advances on basic and clinical research of liver metastasis of pancreatic neuroendocrine tumors

Clinical application of traditional Chinese medicine in the treatment of neuroendocrine neoplasms

Pathogenesis, Biomarkers and Therapeutic Targets

Recent Progress of Experimental Model in Pancreatic Neuroendocrine Tumors: Drawbacks and Challenges

[Tumor Cells and Micro-environment in Brain Metastases].

Neuroendocrine tumor biomarkers: From monoanalytes to transcripts and algorithms

Molecular biology of pancreatic neuroendocrine tumors: From mechanism to translation

Advances in Fundamental and Translational Breast Cancer Research in 2022

Progress of Important Clinical Trials of Breast Cancer in China in 2022

Clinical Intricacies and Advances in Neuroendocrine Tumors: An Organ-Based Multidisciplinary Approach

Research Progress on Treatment of Duodenal Neuroendocrine Neoplasm

Research Progress of Bone Metastases: from Disease Recognition to Clinical Practice.